Safety of Dabigatran Etexilate in Blood Clot Prevention in Children
Status:
Completed
Trial end date:
2019-11-19
Target enrollment:
Participant gender:
Summary
This open-label, single arm prospective cohort study will assess the safety of dabigatran
etexilate in secondary prevention of venous thromboembolism in paediatric patients. Children
from 0 to less than 18 years of age will be eligible to participate.